COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

as the company expects its sales of its popular weight loss drug, Wegovy, to increase in the United States, its biggest market. Novo Nordisk hopes to achieve the same in the quarters ahead ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

Sales of hemophilia A products declined 10%. Hemophilia B products’ sales increased 27%. Sales of NovoSeven decline 5% to DKK 1.9 billion. Sales of Novo Nordisk ... 673.0%. Most of the stocks ...

We recently compiled a list of the 12 Best Stocks to Buy and Hold For 10 Years. In this article, we are going to take a look ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Novo Nordisk (NYSE:NVO) specializes in the research, development, production, and distribution of pharmaceutical products ... the beginning of 2025, while popular AI stocks lost around 25%.